 SOUTH SAN FRANCISCO, Calif., April 05, 2021 GLOBE NEWSWIRE -- Tricida, Inc. Nasdaq: TCDA, a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease CKD, announced today that multiple presentations on the impact of metabolic acidosis and CKD and data on veverimer will be given at the National Kidney Foundation 2021 Spring Clinical Meetings taking place from April 6 to 10, 2021. 